Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACEIs in COVID-19
NCT04345406Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Apr 2020
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of captopril and enalapril in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tanta University. Primary endpoint: Number of patients with virological cure at 6 months. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
captoprilenalapril
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04345406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345406.